ANDREW WEI (MELBOURNE)
DEFINING THE ROLE OF VENETOCLAX IN OLDER PATIENTS WITH AML
Alfred Hospital, Melbourne, Australia
The emergence of venetoclax onto the clinical stage in AML has been striking. The accelerated
approval was based on single-arm phase 1b/2 data, preceding results of a RCT. Although the overall
response rate in combination with HMA and LDAC was impressive compared to historical outcomes,
further critical evaluation is needed to define which patient sub-groups venetoclax is likely to have
an enduring role in. Several topics will be discussed. These include cohort comparisons between
venetoclax-based approaches and competing sub-group options such as IDH, FLT3 mutant and
secondary AML. New data is also emerging on the modifying effects of recurrent AML mutations on
venetoclax response and resistance and their relevance to long-term outcomes. Finally, I will discuss
the initial results of the RCT comparing LDAC + venetoclax vs placebo and the implications of this
study in defining the role of venetoclax in older patients with AML.
SCIENTIFIC
PROGRAMME
RARE SUBSETS OF
ACUTE LEUKAEMIA
TRACKING LEUKAEMIC
STEM CELLS (LSCs)
ROUTINE DIAGNOSIS
GENE EXPRESSION
AND MUTATIONAL
PROFILING
DEBATE 1 – ALL
PATIENTS WITH
INTERMEDIATE-RISK
AML MUST BE
TRANSPLANTED
INTERACTIVE
CASES 1 – MUTATION-BASED
THERAPY
OFF-LABEL
ROUNDTABLE –
SHOULD WE REALLY
USE NEW TARGETED
INHIBITORS AS SINGLE
AGENTS ?
ADDITION OF A 3RD
AGENT TO FRONTLINE
7+3
ROUNDTABLE –
CURATIVE OPTIONS
FOR OLDER AML
INTERACTIVE CASES 2
DEBATE 2 - BEST
TREATMENT FOR
NPM1-MUTATED AML IN
THE NEXT FUTURE ?
ALLOGENEIC
HAEMATOPOIETIC
STEM CELL
TRANSPLANTATION
(HSCT)
IMMUNOTHERAPY FOR
ACUTE LEUKAEMIA
DEBATE 3 - T-ALL:
WHERE ARE WE GOING
NOW?
SELECTED ABSTRACTS
AND CLINICAL
CASES FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
DISCLOSURES